You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Three research teams profiled proteomic, genomic, and other features in lung adenocarcinomas in Asia and other parts of the world, including cases in never-smokers.
A new UK research center is to focus on preventing cancers from developing treatment resistance, New Scientist reports.
Using exome or transcriptome data from more than 400 metastatic, castration-resistant prostate cancer cases, researchers identified survival-related alterations in the RB1 gene.
The group plans to use the assay for translational studies on metastasis and drug resistance initially and to develop a clinical version later on.
Researchers found relevant non-coding mutations in colorectal cancer cell lines by systematically profiling chromosome interactions at promoter fragments.
These and previously uncovered multiple myeloma risk loci may influence disease by affecting developmental transcriptional regulators.
An Institute of Cancer Research-led team has developed a machine-learning tool to predict how tumors may evolve, according to the Telegraph.
Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.
Researchers uncovered subclones within pediatric glioblastoma and diffuse intrinsic pontine glioma patients that influence the abilities of neighboring cells.
Using data for more than 140,000 individuals, researchers narrowed in on 63 new prostate cancer-associated loci and established a polygenic score linked to enhanced risk.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.